PART I Company Overview Unless otherwise provided in this Annual Report, references to the Company, we, us, and our refer to Puma Biotechnology, Inc. and our wholly owned subsidiary. We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment ofcertain HER2-positivebreast cancers.Additionally, we have in-licensed...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001437749-26-005891 | EDGAR | 108K words |
| 2025-02-27 | 2024-12-31 | 0001437749-25-005496 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001437749-24-006121 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001437749-23-005233 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001437749-22-005164 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009840 | EDGAR | — |
| 2020-02-28 | 2019-12-31 | 0001564590-20-007591 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001564590-19-005830 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001564590-18-005152 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001564590-17-003090 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001437749-26-026311 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001437749-25-033633 | EDGAR | 36K words |
| 2025-08-07 | 2025-06-30 | 0001437749-25-025470 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001437749-25-015533 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001437749-24-033955 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001437749-24-024309 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001437749-24-014395 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001437749-23-030028 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001437749-23-021972 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001437749-23-012589 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001437749-22-025787 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001437749-22-018920 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001437749-26-026282 | EDGAR | — |
| 2026-02-26 | 0001437749-26-005869 | EDGAR | 4K words |
| 2025-11-06 | 0001437749-25-033604 | EDGAR | — |
| 2025-08-07 | 0001437749-25-025463 | EDGAR | — |
| 2025-06-24 | 0001437749-25-021153 | EDGAR | — |
| 2025-06-13 | 0001437749-25-020321 | EDGAR | — |
| 2025-05-09 | 0001437749-25-015648 | EDGAR | — |
| 2025-05-08 | 0001437749-25-015514 | EDGAR | — |
| 2025-02-27 | 0001437749-25-005477 | EDGAR | — |
| 2024-11-07 | 0001437749-24-033929 | EDGAR | — |
279 total filings indexed. 247 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001401667 |
| Ticker | PBYI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pumabiotechnology.com |
| Listed | 2012-03-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PBYI (~200 tokens, structured JSON with cryptographic provenance)